The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells

Dong Hoon Lee, Hye Rim Won, Hyun Wook Ryu, Jung Min Han, So Hee Kwon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY-1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY-1215 and anticancer agents in hematological cancers could occur in solid tumors. The results of the present study indicated that ACY-1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells. The combination of ACY-1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY-1215 and oxaliplatin cotreatment activated caspase-3 and poly (ADP ribose) polymerase, increased B-cell lymphoma (Bcl)-2 homologous antagonist/killer expression, and decreased Bcl-extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression. In addition, combined treatment of ACY-1215 and anticancer agents induced synergistic upregulation of programmed death-ligand 1. These findings suggested that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.

Original languageEnglish
Pages (from-to)844-854
Number of pages11
JournalInternational journal of oncology
Volume53
Issue number2
DOIs
Publication statusPublished - 2018 Aug

Fingerprint

oxaliplatin
Colorectal Neoplasms
Antineoplastic Agents
B-Cell Lymphoma
Neoplasms
Proto-Oncogene Proteins c-akt
Histone Deacetylase Inhibitors
Poly(ADP-ribose) Polymerases
2-(diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
Extracellular Signal-Regulated MAP Kinases
Hematologic Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{9b5810d8aff048618052c2a01e8d8797,
title = "The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells",
abstract = "ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY-1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY-1215 and anticancer agents in hematological cancers could occur in solid tumors. The results of the present study indicated that ACY-1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells. The combination of ACY-1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY-1215 and oxaliplatin cotreatment activated caspase-3 and poly (ADP ribose) polymerase, increased B-cell lymphoma (Bcl)-2 homologous antagonist/killer expression, and decreased Bcl-extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression. In addition, combined treatment of ACY-1215 and anticancer agents induced synergistic upregulation of programmed death-ligand 1. These findings suggested that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.",
author = "Lee, {Dong Hoon} and Won, {Hye Rim} and Ryu, {Hyun Wook} and Han, {Jung Min} and Kwon, {So Hee}",
year = "2018",
month = "8",
doi = "10.3892/ijo.2018.4405",
language = "English",
volume = "53",
pages = "844--854",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. / Lee, Dong Hoon; Won, Hye Rim; Ryu, Hyun Wook; Han, Jung Min; Kwon, So Hee.

In: International journal of oncology, Vol. 53, No. 2, 08.2018, p. 844-854.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells

AU - Lee, Dong Hoon

AU - Won, Hye Rim

AU - Ryu, Hyun Wook

AU - Han, Jung Min

AU - Kwon, So Hee

PY - 2018/8

Y1 - 2018/8

N2 - ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY-1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY-1215 and anticancer agents in hematological cancers could occur in solid tumors. The results of the present study indicated that ACY-1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells. The combination of ACY-1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY-1215 and oxaliplatin cotreatment activated caspase-3 and poly (ADP ribose) polymerase, increased B-cell lymphoma (Bcl)-2 homologous antagonist/killer expression, and decreased Bcl-extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression. In addition, combined treatment of ACY-1215 and anticancer agents induced synergistic upregulation of programmed death-ligand 1. These findings suggested that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.

AB - ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY-1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY-1215 and anticancer agents in hematological cancers could occur in solid tumors. The results of the present study indicated that ACY-1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells. The combination of ACY-1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY-1215 and oxaliplatin cotreatment activated caspase-3 and poly (ADP ribose) polymerase, increased B-cell lymphoma (Bcl)-2 homologous antagonist/killer expression, and decreased Bcl-extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression. In addition, combined treatment of ACY-1215 and anticancer agents induced synergistic upregulation of programmed death-ligand 1. These findings suggested that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.

UR - http://www.scopus.com/inward/record.url?scp=85049040316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049040316&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4405

DO - 10.3892/ijo.2018.4405

M3 - Article

C2 - 29749542

AN - SCOPUS:85049040316

VL - 53

SP - 844

EP - 854

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -